Magazine Article | September 1, 2022

Our Long Journey To FDA Approval

Source: Life Science Leader

By Michael Bailey

The humanity of those we serve in the life sciences is especially important to keep top-of mind today as the financial markets buffet small biotechs with both positive and negative news alike. During these challenging times, CEOs need to remember that we are privileged to pursue such a noble cause that is undiminished by market volatility. The financial markets, though, weren’t the cause of one of the most difficult periods, I faced as CEO of AVEO Oncology. Instead, it was the decade-long journey we took to gain approval of our flagship kidney cancer drug, FOTIVDA (tivozanib), after significant regulatory and organizational setbacks

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: